Pfizer's PF-08046052: A Significant Milestone in Clinical Development. LAVA Therapeutics N.V., a leader in the biotechnology sector, has recently announced a significant clinical development milestone achieved by Pfizer for the drug PF-08046052. This milestone has prompted the first payment of $7 million to LAVA, marking a notable event in the field of immuno-oncology.$LAVA Therapeutics(LVTX.US)$ https://stockregion.app/p/biotech-leader-announces-7m-milestone
LAVA Therapeutics股票討論區
LAVA Therapeutics N.V., a leader in the biotechnology sector, has recently announced a significant clinical development milestone achieved by Pfizer for the drug PF-08046052. This milestone has prompted the first payment of $7 million to LAVA, marking a notable event in the field of immuno-oncology. $LAVA Therapeutics(LVTX.US)$
https://stockregion.app/p/biotech-leader-announces-7m-milestone
暫無評論